Literature DB >> 19888384

Overview of glycemic control in critical care: relating performance and clinical results.

J Geoffrey Chase1, Christopher E Hann, Geoffrey M Shaw, Jason Wong, Jessica Lin, Thomas Lotz, Aaron Lecompte, Timothy Lonergan.   

Abstract

BACKGROUND: Hyperglycemia is prevalent in critical care and tight control can save lives. Current ad-hoc clinical protocols require significant clinical effort and produce highly variable results. Model-based methods can provide tight, patient specific control, while addressing practical clinical difficulties and dynamic patient evolution. However, tight control remains elusive as there is not enough understanding of the relationship between control performance and clinical outcome.
METHODS: The general problem and performance criteria are defined. The clinical studies performed to date using both ad-hoctitration and model-based methods are reviewed. Studies reporting mortality outcome are analysed in terms of standardized mortality ratio (SMR) and a 95(th) percentile (+/-2sigma) standard error (SE(95%)) to enable better comparison across cohorts.
RESULTS: Model-based control trials lower blood glucose into a 72-110 mg/dL band within 10 hours, have target accuracy over 90%, produce fewer hypoglycemic episodes, and require no additional clinical intervention. Plotting SMR versus SE(95%) shows potentially high correlation (r=0.84) between ICU mortality and tightness of control.
SUMMARY: Model-based methods provide tighter, more adaptable one method fits all solutions, using methods that enable patient-specific modeling and control. Correlation between tightness of control and clinical outcome suggests that performance metrics, such as time in a relevant glycemic band, may provide better guidelines. Overall, compared to the current one size fits all sliding scale and ad-hoc regimens, patient-specific pharmacodynamic and pharmacokinetic model-based, or one method fits all control, utilizing computational and emerging sensor technologies, offers improved treatment and better potential outcomes when treating hyperglycemia in the highly dynamic critically ill patient.

Entities:  

Keywords:  clinical control; glucose variability; hyperglycemia; metabolism; model-based; mortality; results

Year:  2007        PMID: 19888384      PMCID: PMC2769615          DOI: 10.1177/193229680700100113

Source DB:  PubMed          Journal:  J Diabetes Sci Technol        ISSN: 1932-2968


  66 in total

1.  Intensive versus modified conventional control of blood glucose level in medical intensive care patients: a pilot study.

Authors:  David Kelvin Bland; Yvonne Fankhanel; Eileen Langford; Martha Lee; Scott W Lee; Colleen Maloney; Mark Rogers; Grenith Zimmerman
Journal:  Am J Crit Care       Date:  2005-09       Impact factor: 2.228

2.  Glycemic control needs a standard reference point.

Authors:  Stephen C Gale; Vicente H Gracias
Journal:  Crit Care Med       Date:  2006-06       Impact factor: 7.598

Review 3.  Alterations in fuel metabolism in critical illness: hyperglycaemia.

Authors:  B A Mizock
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2001-12       Impact factor: 4.690

4.  Action without benefit. The sliding scale of insulin use.

Authors:  C T Sawin
Journal:  Arch Intern Med       Date:  1997-03-10

5.  Sliding scale insulin use.

Authors:  H B Radack
Journal:  Arch Intern Med       Date:  1997 Aug 11-25

6.  CD14 monocyte receptor, involved in the inflammatory cascade, and insulin sensitivity.

Authors:  José Manuel Fernández-Real; Montserrat Broch; Cristóbal Richart; Joan Vendrell; Abel López-Bermejo; Wifredo Ricart
Journal:  J Clin Endocrinol Metab       Date:  2003-04       Impact factor: 5.958

7.  Glycemic control and sliding scale insulin use in medical inpatients with diabetes mellitus.

Authors:  W S Queale; A J Seidler; F L Brancati
Journal:  Arch Intern Med       Date:  1997-03-10

8.  Adaptive bolus-based targeted glucose regulation of hyperglycaemia in critical care.

Authors:  J Geoffrey Chase; Geoffrey M Shaw; Jessica Lin; Carmen V Doran; Chris Hann; Michael B Robertson; Patrick M Browne; Thomas Lotz; Graeme C Wake; Bob Broughton
Journal:  Med Eng Phys       Date:  2005-01       Impact factor: 2.242

9.  Quantifying temporal glucose variability in diabetes via continuous glucose monitoring: mathematical methods and clinical application.

Authors:  Boris P Kovatchev; William L Clarke; Marc Breton; Kenneth Brayman; Anthony McCall
Journal:  Diabetes Technol Ther       Date:  2005-12       Impact factor: 6.118

10.  Association of hyperglycemia and markers of hepatic dysfunction with dextrose infusion rates in Korean patients receiving total parenteral nutrition.

Authors:  Hyunah Kim; Eunsun Son; Jungtae Kim; Kyungeob Choi; Choongbae Kim; Wangyoon Shin; Okkyung Suh
Journal:  Am J Health Syst Pharm       Date:  2003-09-01       Impact factor: 2.637

View more
  5 in total

Review 1.  A Review of Emerging Technologies for the Management of Diabetes Mellitus.

Authors:  Konstantia Zarkogianni; Eleni Litsa; Konstantinos Mitsis; Po-Yen Wu; Chanchala D Kaddi; Chih-Wen Cheng; May D Wang; Konstantina S Nikita
Journal:  IEEE Trans Biomed Eng       Date:  2015-08-19       Impact factor: 4.538

2.  The artificial pancreas: how sweet engineering will solve bitter problems.

Authors:  David C Klonoff
Journal:  J Diabetes Sci Technol       Date:  2007-01

3.  A benchmark data set for model-based glycemic control in critical care.

Authors:  J Geoffrey Chase; Aaron LeCompte; Geoffrey M Shaw; Amy Blakemore; Jason Wong; Jessica Lin; Christopher E Hann
Journal:  J Diabetes Sci Technol       Date:  2008-07

4.  The impact of parameter identification methods on drug therapy control in an intensive care unit.

Authors:  Christopher E Hann; J Geoffrey Chase; Michael F Ypma; Jos Elfring; Noorhafiz Mohd Nor; Piers Lawrence; Geoffrey M Shaw
Journal:  Open Med Inform J       Date:  2008-05-27

5.  Implementation and evaluation of the SPRINT protocol for tight glycaemic control in critically ill patients: a clinical practice change.

Authors:  J Geoffrey Chase; Geoffrey Shaw; Aaron Le Compte; Timothy Lonergan; Michael Willacy; Xing-Wei Wong; Jessica Lin; Thomas Lotz; Dominic Lee; Christopher Hann
Journal:  Crit Care       Date:  2008-04-16       Impact factor: 9.097

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.